Evidence map›Paper›PMID 37681960›Full record

ArticleJournal of virology2023

Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an antiviral drug screening platform.

Shigeo Nagashima, Putu Prathiwi Primadharsini, Takashi Nishiyama, Masaharu Takahashi, Kazumoto Murata, Hiroaki Okamoto

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shigeo NagashimaDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0001-8944-713X
Putu Prathiwi PrimadharsiniDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0001-7401-979X
Takashi NishiyamaDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0002-4496-240X
Masaharu TakahashiDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0001-6888-9318
Kazumoto MurataDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0002-3419-6297
Hiroaki OkamotoDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine , Tochigi, Japan.ORCID 0000-0003-0827-0964
Jichi Medical University · JP

Funding

Japan Agency for Medical Research and Development (AMED) JP22fk0210075, JP23fk0210132MEXT | Japan Society for the Promotion of Science (JSPS) 22K07105Takeda Science Foundation (TSF)
6 · The paper itself

Abstract

Previously, we developed an infectious hepatitis E virus (HEV) harboring the nanoKAZ gene in the hypervariable region of the open reading frame 1 (ORF1) of the HEV3b (JE03-1760F/P10) genome and demonstrated the usefulness for screening anti-HEV drugs that inhibit the early infection process. In the present study, we constructed another reporter HEV (HEV3b-HiBiT) by placing a minimized HiBiT tag derived from NanoLuc luciferase at the 3'-end of the viral capsid (ORF2) coding sequence. It replicated efficiently in PLC/PRF/5 cells, produced membrane-associated particles identical to those of the parental virus, and was genetically stable and infectious. The HiBiT tag was fused to both secreted ORF2s (ORF2s-HiBiT) and ORF2c capsid protein (ORF2c-HiBiT). The ORF2c-HiBiT formed membrane-associated HEV particles (eHEV3b-HiBiT). By treating these particles with digitonin, we demonstrated that the HiBiT tag was expressed on the surface of capsid and was present inside the lipid membrane. To simplify the measurement of luciferase activity and provide a more convenient screening platform, we constructed an ORF2s-defective mutant (HEV3b-HiBiT/ΔORF2s) in which the secreted ORF2s are suppressed. We used this system to evaluate the effects of introducing small interfering RNAs and treatment with an inhibitor or accelerator of exosomal release on HEV egress and demonstrated that the effects on virus release can readily be analyzed. Therefore, HEV3b-HiBiT and HEV3b-HiBiT/ΔORF2s reporters may be useful for investigating the virus life cycle and can serve as a more convenient screening platform to search for candidate drugs targeting the late stage of HEV infection such as particle formation and release. IMPORTANCE The construction of recombinant infectious viruses harboring a stable luminescence reporter gene is essential for investigations of the viral life cycle, such as viral replication and pathogenesis, and the development of novel antiviral drugs. However, it is difficult to maintain the stability of a large foreign gene inserted into the viral genome. In the present study, we successfully generated a recombinant HEV harboring the 11-amino acid HiBiT tag in the ORF2 coding region and demonstrated the infectivity, efficient virus growth, particle morphology, and genetic stability, suggesting that this recombinant HEV is useful for

Indexed as

Antiviral AgentsGenes, ReporterHepatitis E virusCapsid ProteinsCell LineDrug Evaluation, PreclinicalHepatitis EHumansLuciferasesOpen Reading FramesViral ProteinsVirus ReplicationAntiviral AgentsCapsid ProteinsLuciferasesViral Proteinsbioluminescent proteindrug screeninghepatitis E virusHiBiT tagORF2 capsid proteinreporter virusvirus release

Identifiers

PMID37681960
PMCPMC10537679
OpenAlexW4386529963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.